W4
Synthetic lignans targeting cardiovascular diseases
Prof. Marko Mihovilovic, Technical University Vienna; Dr Thomas Linder, Technical University Vienna; Prof. Verena M. Dirsch, University of Vienna; Dr David Bernhard, University of Innsbruck; Prof. Hermann Stuppner, University of Innsbruck
Austria Wirtschaftsservice
Challenge
Within a joint research approach researchers at Vienna University of Technology, University of Innsbruck, Vienna University and Medical University of Vienna have identified novel synthetic lignans to affect inflammatory processes related to surgical cardiovascular intervention.
Technology
Novel synthetic lignans to affect inflammatory processes related to surgical cardiovascular intervention have been identified. Starting from natural compound leoligin, improved synthetic analogs were prepared with favourable properties to prevent VSMC proliferation concomitantly not affecting EC to keep blood vessel structural integrity unaffected.
The novel compounds may have highly beneficial effects for preparation of cardiac by-pass implants as well as for stent conduits. Potential applications range from administration within by-pass preparation to controlled-release devices for stents.
Commercial Opportunity
Collaboration, License, Purchase
Development Status
Lead optimization
Patent Situation
Priority 2014
AT, EP, US patents filed
Further Reading
WO2015196228 A1
Starting from natural compound leoligin, improved synthetic analogs were prepared